Post on 15-Jan-2016
INDOCO REMEDIES LTD
1
Company Profile
A fast growing, fully integrated, research oriented pharmaceutical company with a Global presence.
Strong domestic marketing setup with PAN India presence.
Workforce of over 4000- 200 R&D scientists -1800 Field staff
Revenues in FY 2010-11 Rs. 4800 mn. (US$ 100 mn) (Domestic & International contribution 65 % & 35% respectively)
Listed on Stock Exchanges in India
2
Our Infrastructure
Corporate Office at Santacruz (E), Mumbai
9 Manufacturing Facilities 5 – FDFs 4 – APIs
R&D Centre at Navi Mumbai
35 Depots & Branches
3
Mfg. Facilities for FDFs
LOCATIONDOSAGE
FORMAPPROVALS
GOA ITABLETS,
CREAMS & OINTMENTS
EU - GMP, Australia, South Africa
GOA IISTERILE
PRODUCTSEU - GMP, USA,
South Africa
GOA III TABLETS Awaited
WALUJ TABLETS Emerging Markets
BADDITABLETS,
LIQUID ORALS & TOOTHPASTES
EU – GMP
4
API Facilities
Kilo Scale: Navi Mumbai Reaction Systems: 16 to 500 L Total Reactor Volume: 1 cubic meters Temperatures range: -55 to + 150
celsius
Multi-ton : Patalganga (I) Reactor Capacity: 500 to 5000 L
Mid-Volume : Patalganga (II) Reactor Capacity: 500 to 2000 L
Intermediates : Rabale Reactor Capacity: 500 to 3000 L Total Reactor Volume: 50 cubic meters
5
Research & Development
US $ 10 million Investment
Spread over an area of 100,000 square feet and employs over 200 scientists and technical personnel
34 Patents filed
R&D activities include: - Chemical synthesis of APIs and Intermediates with non-infringing processes - Formulation Development including NDDS and new technology platforms - Analytical Research - Regulatory services 6
Branded
Generics APIs
Regulated Markets
- Alliances - Customer
Network Emerging
Markets - Distributor
Model
Covers 80 countries Licensing out CRAMS Branded Generics
18 Therapeutic
Segments 160 Brands 8 Marketing
Divisions
Indian Business
Business Model
International
Business
Vertically Integrated
7
Indian Business
INDOCO – GP, CP, Gynaec
SPADE – GP, CP, Paediatrician, ENT
WARREN –Dental
EXCEL – Opthal
SPERA – GP, Gynaec, Paediatrician
ETERNA – CPs, Orthos, Gastro
XTEND – GPs in Extra Urban Towns
CND – Lifestyle/Cardio & Diabetology Ranked 27th by CMARC in Rx Ranking (Dec’ 2011) Ranked 30th by AWACS in SSA Audit (Jan’ 2012)
8
Brand Therapeutic Areas Rank Market Share
HOMIDE Ophthalmic 1 91.70%CYCLOPAM Anti-Spasmodic 1 54.30%CITAL Urinary Alkalizer 1 30.80%SENSODENT-K Desensitizing Toothpaste 1 7.30%SENSOFORM Desensitizing Toothpaste 1 5.30% SCABEX Scabies Skin Cream 2 23.80%CLOBEN-G Antifungal Skin Cream 2 11.90%CARMICIDE Anti-Flatulent 2 17.00%ATM Anti-Infectiver 2 9.30% VEPAN Anti-Infective 3 16.20%FEBREX PLUS Anti-Cold 3 9.20% KARVOL PLUS Nasal Decongestant 4 6.30%NOSIC Anti-Emetic 4 4.70% HEMSYL Gynaec 5 10.30%GLYCHEK-M Anti-Diabetic 5 6.90%TUSPEL PX Cough Syrup 5 4.10%OXIPOD Anti-Infective 5 3.60%
Few Brands which occupy leadership position (among top 5)
9
Growth Drivers (Domestic Business)
• Growing middle class population, increasing income levels, rapid urbanization, demand for quality healthcare services & changing lifestyle
• Focus in high potential territories such as tier-III towns and rural areas
• Product introductions in newer segments and therapies
• Intensive Pan – India coverage of the Medical Fraternity through various marketing divisions
• Thrust area for the Company
10
Regulated Markets
International Business
Emerging Markets
11
Growth Drivers (International Business)
• Strong relationship with Watson Pharmaceuticals Inc., USA
• Multi-product, Multi-territory alliance with Aspen Pharmacare, SA and extended to Sigma, Australia (Aspen’s acquisition)
• Alliance with DSM, a € 9 billion company, for marketing & distribution of APIs
• NDDS and new technology platforms
• New manufacturing facility at Goa to cater to the growing demand for supplies
• Registration of own Dossiers and Out-licensing of MA’s in Regulated Markets
12
(Rs. In Lacs)
Sr.No. Particulars Quarter ended
31.12.2011 (Unaudited)
Quarter ended 30.09.2011
(Unaudited)
Quarter ended 31.12.2010
(Unaudited)
Nine months ended
31.12.2011 (Unaudited)
Nine months ended
31.12.2010 (Unaudited)
Year ended 31.03.2011 (Audited)
1 Net Sales / Income from Operations 14,152 14,474 11,431 41,181 35,803 47,847
(b) Other Operating income 106 266 116 523 548 795
Total (a+b) 14,258 14,740 11,547 41,704 36,351 48,642
2 Expenditure : 13,162 13,140 10,440 37,540 31,910 42,748
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)
1,096 1,600 1,107 4,164 4,441 5,894
4 Other Income - 5 2 5 3 5
5 Profit before Interest and Exceptional Items (3+4) 1,096 1,605 1,109 4,169 4,444 5,899
6 Interest 180 144 59 412 177 240
7 Profit after Interest but before Exceptional Items (5-6)
916 1,461 1,050 3,757 4,267 5,659
8 Exceptional Items - - - - - -
9 Profit from Ordinary Activities before tax (7+8) 916 1,461 1,050 3,757 4,267 5,659
10 Tax Expenses 90 80 169 376 378 547
11 Net Profit from Ordinary Activities after tax (9-10) 826 1,381 881 3,381 3,889 5,112
12 Extraordinary Items - - - - - -
13 Net Profit for the period (11-12) 826 1,381 881 3,381 3,889 5,112
14 Paid up Equi ty Share Capi ta l (Face va lue Rs .10/- each) 1,228.67 1,228.67 1,228.67 1,228.67 1,228.67 1,228.67
15 Reserves excluding Reva luation Reserves - - 33,791
16 Earning Per Share (EPS) - Not Annualised - Rs.
(a) Basic and diluted EPS before Extraordinary Items 6.72 11.24 7.17 27.52 31.65 41.60
(b) Basic and diluted EPS after Extraordinary Items 6.72 11.24 7.17 27.52 31.65 41.60
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2011
13
Thank You….. 14